Intellia Therapeutics Statistics

Total Valuation

Intellia Therapeutics has a market cap or net worth of GBP 910.48 million. The enterprise value is 225.96 million.

Market Cap	910.48M
Enterprise Value	225.96M

Important Dates

The next estimated earnings date is Thursday, February 20, 2025.

Earnings Date	Feb 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+11.02%
Shares Change (QoQ)	+4.15%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	100.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	1.27
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.58
EV / Sales	6.46
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.83

Financial Position

The company has a current ratio of 6.73, with a Debt / Equity ratio of 0.11.

Current Ratio	6.73
Quick Ratio	6.31
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	-0.28
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -52.23% and return on invested capital (ROIC) is -30.28%.

Return on Equity (ROE)	-52.23%
Return on Assets (ROA)	-27.81%
Return on Capital (ROIC)	-30.28%
Revenue Per Employee	61,115
Profits Per Employee	-740,829
Employee Count	526
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -59.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-59.58%
50-Day Moving Average	13.22
200-Day Moving Average	20.08
Relative Strength Index (RSI)	38.10
Average Volume (20 Days)	15,551

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.26

Income Statement

In the last 12 months, Intellia Therapeutics had revenue of GBP 32.15 million and -389.68 million in losses. Loss per share was -4.06.

Revenue	32.15M
Gross Profit	-309.88M
Operating Income	-401.18M
Pretax Income	-389.68M
Net Income	-389.68M
EBITDA	-393.58M
EBIT	-401.18M
Loss Per Share	-4.06

Full Income Statement

Balance Sheet

The company has 491.02 million in cash and 75.82 million in debt, giving a net cash position of 629.01 million.

Cash & Cash Equivalents	491.02M
Total Debt	75.82M
Net Cash	629.01M
Net Cash Per Share	n/a
Equity (Book Value)	718.21M
Book Value Per Share	7.06
Working Capital	451.55M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -266.16 million and capital expenditures -4.71 million, giving a free cash flow of -270.88 million.

Operating Cash Flow	-266.16M
Capital Expenditures	-4.71M
Free Cash Flow	-270.88M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,247.99%
Pretax Margin	-1,212.19%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Intellia Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.02%
Shareholder Yield	-11.02%
Earnings Yield	-42.80%
FCF Yield	-29.75%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Intellia Therapeutics has an Altman Z-Score of 3.61.

Altman Z-Score	3.61
Piotroski F-Score	n/a